Of the numerous angiogenesis pathways, the VEGF/VEGFR receptor signaling pathway has been verified as the target of HCC precision medicine, which is targeted to inhibit angiogenesis and achieve the treatment for advanced HCC by sorafenib [11–13]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.